Reviewing Ovid Therapeutics (OVID) & Lipocine (LPCN)

Ovid Therapeutics (NASDAQ: OVID) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for Ovid Therapeutics and Lipocine, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics 0 0 5 0 3.00
Lipocine 0 1 3 0 2.75

Ovid Therapeutics currently has a consensus target price of $22.33, suggesting a potential upside of 160.30%. Lipocine has a consensus target price of $13.50, suggesting a potential upside of 800.00%. Given Lipocine’s higher possible upside, analysts clearly believe Lipocine is more favorable than Ovid Therapeutics.


This table compares Ovid Therapeutics and Lipocine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ovid Therapeutics N/A -86.05% -80.34%
Lipocine N/A -90.49% -78.57%

Institutional and Insider Ownership

31.8% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 17.8% of Lipocine shares are held by institutional investors. 11.3% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ovid Therapeutics and Lipocine’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ovid Therapeutics N/A N/A -$22.41 million N/A N/A
Lipocine N/A N/A -$20.98 million ($1.04) -1.44

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Lipocine Company Profile

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply